Please wait while we load the price list

Medical Marketing and Media - GfK forecast: sharp decline in Vytorin, Zetia

November 20th, 2008

QUESTIONS OVER the efficacy of Vytorin and Zetia could prompt a sharp pullback on firstand second-line use of the drug, according to a survey of physicians by GfK Market Measures, but docs are taking a wait-andsee approach with the drugs and remain open to new data.
The study found gene…

Does The F.D.A. Hide Negative Drug Study Results?

November 16th, 2008

Think the Food and Drug Administration (FDA) is here to protect you?
It isn’t.
Think your doctor makes decisions about your health based on medical science?
Not so fast.
Truth is, half of medical evidence is…

Deseret News (Salt Lake City) - Vytorin and Zetia fail in heart study

November 14th, 2008

CHICAGO — Leading doctors urged a return to older, tried-and- true treatments for high cholesterol after hearing full results Sunday of a failed trial of Vytorin and related drug Zetia.
Millions of Americans already take the drug or one of its components, Zetia. But doctors were stunned to learn that Vytorin failed to improve heart disease even though it worked as in…

Lipitor

November 12th, 2008

Timely medication and prompt diagnosis is one of the best ways to avert major health problems. One of the biggest health problems in today fast paced world in dietary changes that leads to a high intake of fatty substances that leads to high amount of cholesterol and thickening the blood vessels and leading to coronary disease and many other health complications that can be fatal in nature. So, in case one is looking for a perfect medication that helps …

Health News - Zetia + statin greatly decreases LDL cholesterol

November 9th, 2008

Statins reduce the amount of cholesterol the liver makes, and ezetimibe (Zetia) prevents the intestine from absorbing cholesterol, used together these drugs lower LDL (”bad”) cholesterol much more than either drug alone. In a U.K. study reported in Current Medical Research and opinion, 148 patients received ezetimibe plus atorvastatin (Lipitor) or atorvastatin alone.

Related Results

AMAA Journal - Statin myopathy: a brief review

November 7th, 2008

The controversy surrounding the highly promoted cholesterol-lowering drug Vytorin continued Friday when U.S. health officials said they would review the medication’s effectiveness, but only after final trial results were completed.
a combination of two cholesterol drugs — had little medical benefit.
“We have not yet received a final study report and can’t explain why Vytorin didn’t lead to lesser amounts of plaque compared to patients treated with simvastatin alone,” Dr. Jo…

Availability of lipitor drug online

November 3rd, 2008

Lipitor is a part of the drug family statins that are widely used for reducing the amount of cholesterol in the human body. They inhibit the rate determining enzymes that are located in the hepatic tissues and produce mevalonate. Mevalonate is a molecule that is used in cholesterol synthesis and the production of other derivatives of melavonate. As per the recent studies, lip…

Zetia and Vytorin: Let’s Look at the Facts

October 30th, 2008

Let’s talk about the current media frenzy about the results of a study that seems to conclude that Zetia may not be effective for treating high cholesterol: the ENHANCE study. After the reports were published, I got a bunch of telephone calls from patients and family who are either on Vytorin or on Zetia in combination with another statin and they want to know about what to do now.My response to them is to relax, and please read this post. I…

Business Wire - Niaspan® Combined with Low/Moderate Dosed Statin Achieves Better Total Lipid Control vs. Higher Dose Statin Monotherapy or Zocor

October 26th, 2008

CRANBURY, N.J. — Kos Pharmaceuticals, Inc. (Nasdaq: KOSP):
–COMPELL study shows significantly greater reductions in triglycerides and Lp(a), as well as superior 2.5-3.5 fold increases in HDL-C and comparable lowering of LDL-C with Niaspan combination therapy versus Crestor(R) and Zocor/Zetia

Business Wire - New Analysis in Patients with Type 2 Diabetes from Trial with VYTORIN-TM- -ezetimibe/simvastatin- Presented at ADA; Consistent with Overall Study which Showed…

October 23rd, 2008

PHILADELPHIA — According to research from Cognet-X, Inc., conducted after Merck/Schering-Plough released its ENHANCE study results, pharmacy and medical executives at managed health care companies see few immediate changes in how their organizations cover the cholesterol reducers Vytorin and Zetia.
However, utilization of the brands is expected to decrease after ENHANCE showed that Vytorin - a combination of the statin simvastati…